Innovate Drug In Pharmaceutical Company Product Pipeline To Boost The Neuroendocrine Tumor Treatment Market
The Global Neuroendocrine Tumor Treatment Market was valued at US$ 1,197.3 million in 2016 and is projected to expand at a CAGR of 10.5% during the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Better diagnostic techniques and products in pipeline are expected to be major factors driving growth of the global neuroendocrine tumor treatment market over the foreseeable future.
Neuroendocrine Tumor (NET) are diagnosed more frequently in the U.S. than other countries worldwide. According to U.S. Surveillance Epidemiology and End Results (SEER) Register, in 35 years prior to 2016, the number of GI neuroendocrine tumors/carcinomas of the small intestine has increased 300%-500%, which will drive an ample opportunity for the emerging pharma companies focusing on neuroendocrine tumor treatment drugs. Pulmonary neuroendocrine tumor treatment comprise around 25% of all kinds of neuroendocrine tumor treatment. According to Louisiana State University Health Sciences Center, 2016, Pulmonary Neuroendocrine Tumor Treatment have a low incidence in the U.S., with a rate of 1.6/100,000 individuals. Typical Carcinoid (TC) comprise 1-2% and Atypical Carcinoid (AC) comprise 0.1-0.2% of all pulmonary tumors, whereas small cell lung carcinoma (SCLC) and Large Cell Neuroendocrine Carcinoma (LCNECs) make up 20% and 1.6-3%, respectively
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/129
Overall survival is good for the well-differentiated Typical Carcinoid tumors is 92-100% and moderate for AC 61-88%, whereas the higher grade, poorly differentiated SCLC and LCNET have a grim prognosis with OS as low as 5%
According to stats released by the American Society of Clinical Oncology in 2014, an estimated 12,000 people are diagnosed with a neuroendocrine tumor and 1,500 people are diagnosed with Merkel cell skin cancer in the U.S. each year. Most of the patients were in the age group 60-65 years, with 90% are white people. This disease if undiagnosed within the first two years of its occurrence, reduces survival rate to around 60%. Survival rate of neuroendocrine cancer becomes much higher if it is detected in early stages, prior spreading to the lymph nodes or any distant parts of the human body. The GI neuroendocrine tumor is the one of the most common indication causing liver metastases, particularly when it effected in the midgut origin. Appendix is the second most common location for midgut carcinoids it acts as a carrier for the spread of the disease to entire liver.
Around 90 out of 100 people survive for 5 years or more if the carcinoid started in the appendix gastrointestinal neuroendocrine tumors is inherently a diverse group of cells or tumors that sometimes generate various peptides triggering characteristic hormonal disorders. Neuroendocrine tumor treatment can be categorized into clinically symptomatic (functioning) or silent (non-functioning). Both types of NET produce more than one peptide, though these are not associated with specific syndromes.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/129
Key takeaways of the neuroendocrine tumor treatment market:
The global neuroendocrine tumor treatment market is expected to expand at a CAGR of 10.5% during the forecast period (2017–2025) as there exists a huge unrealized market especially in Asia Pacific, Latin America, Middle East and Africa
The Sunitinib Malate and Sufatinib dominates the market in the drug segment, as it is used to treat progressive, well-differentiated advanced and/or metastatic pancreatic neuroendocrine tumors and show a good tolerance in Grade 3 NET patients too.
Gastrointestinal neuroendocrine tumor and pancreatic neuroendocrine tumor are the major indication segment of neuroendocrine tumor treatment market, as these indication are highly prevalent in regions like North America and Asia Pacific
Some of the major players involved in global neuroendocrine tumor treatment market are Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc.and Exelixis, Inc.
You may be interested
Autoclave Market Analysis of Sales, Revenue, Share and Growth And Companies MELAG Medizintechnik oHG, Tuttnauer, Getinge AB, Belimed, SAKURA SEIKIAlbert R - September 25, 2018
According to a new market research study titled Autoclave Market to 2026 Global Analysis and Forecasts by Material Composition, Industries and End Products, The report highlights…
Optometry Equipment Market Emerging Trends,Forecasts 2018-2025 And Major Key Companies Canon, Carl Zeiss AG, Escalon Servicesc., Essilor International S.A., Haag-StreitAlex Mathew - September 25, 2018
According to a new market research study titled Optometry Equipment Market to 2026 Global Analysis and Forecasts by Material Composition, Industries and End Products, The report…
Patient Engagement Solution Market Share, Growth, Outlook to 2025 And Top Companies Allscripts, Cerner Corporation, Conifer Health Solutions, HealthagenRachel Stinson - September 25, 2018
According to a new market research study titled Patient Engagement Solution Market to 2026 Global Analysis and Forecasts by Material Composition, Industries and End Products, The…